Drug and Therapeutics Bulletin 2003;41:52-54; doi:10.1136/dtb.2003.41752
Copyright © 2003 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Nateglinide and {blacktriangledown}repaglinide for type 2 diabetes?

Relevant BNF section: 6.1.2.3

{blacktriangledown}Nateglinide (Starlix - Novartis) and {blacktriangledown}repaglinide (NovoNorm - Novo Nordisk) are two of a new class of orally active antidiabetic drugs, the meglitinides. They have a rapid-onset and short-lasting stimulating effect on insulin secretion. Both are licensed for combination therapy with metformin in patients with type 2 diabetes mellitus who are inadequately controlled by maximally tolerated doses of metformin alone. In addition, repaglinide is licensed for use as monotherapy in patients with type 2 diabetes whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Here we discuss whether repaglinide and nateglinide offer worthwhile advantages in the management of patients with type 2 diabetes.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2003 BMJ Publishing Group Ltd.